Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19

• Published in: mBio 2022-06, Vol.13 (3), p.e0018122-e0018122
• Main Authors: Zhao, Wei, Chen, Weixin, Li, Juan, Chen, Meng, Li, Qin, Lv, Min, Zhou, ShanShan, Bai, Shuang, Wang, Yali, Zhang, Lichi, Zhang, Peng, Wang, Jian, Zheng, Qun, Wu, Jiang
• Format: Article
• Language: English
• Subjects: 12 months; CoronaVac; COVID-19 vaccine; neutralizing antibody; Research Article; T cells; Vaccines
• ISSN: 2150-7511; 2150-7511
• DOI: 10.1128/mbio.00181-22

Understanding immune memory to COVID-19 vaccines is critical for the design and optimal vaccination schedule for curbing the COVID-19 pandemic. Here, we assessed the status of humoral and cellular immune responses at 1, 3, 6, and 12 months after two-dose CoronaVac vaccination. A total of 150 participants were enrolled, and 136 of them completed the study through the 12-month endpoint. Our results show that, at 1 month after vaccination, both binding and neutralizing antibodies could be detected; the seropositive rate of binding antibodies and seroconversion rate of neutralizing antibodies were 99% and 50%, respectively. From 3 to 12 months, the binding and neutralizing antibodies declined over time. At 12 months, the binding and neutralizing antibodies were still detectable and significantly higher than the baseline. Gamma interferon (IFN-γ) and interleukin 2 (IL-2) secretion specifically induced by the receptor-binding domain (RBD) persisted at high levels until 6 months and could be observed at 12 months, while the levels of IL-5 and granzyme B (GzmB) were hardly detected, demonstrating a Th1-biased response. In addition, specific CD4 T central memory (T ), CD4 effector memory (T ), CD8 T , and CD8 terminal effector (T ) cells were all detectable and functional up to 12 months after the second dose, as the cells produced IFN-γ, IL-2, and GzmB in response to stimulation of SARS-CoV-2 RBD. Our work provides evidence that CoronaVac induced not only detectable binding and neutralizing antibody responses, but also functional SARS-CoV-2-specific CD4 and CD8 memory T cells for up to 12 months. CoronaVac is an inactivated vaccine containing whole-virion SARS-CoV-2, which has been approved in 43 countries for emergency use as of 26 November 2021. However, the long-term immune persistence of the CoronaVac vaccine is still unknown. Here, we reported the status of the persistence of antibodies and cellular responses within 12 months after two doses of CoronaVac. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.